Nifty Pharma Stocks to Buy in November 2026: 5 Names on the Watchlist
- November 5, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Sun Pharma Rs 1,773. Lupin Rs 2,009. Divi’s Labs Rs 10,038. Ipca Labs Rs 1,972. Ajanta Pharma Rs 3,317. NSE closing prices, 4 Nov 2026.
Quick Answer
Five Nifty Pharma stocks to buy on the November 2026 watchlist are Sun Pharmaceutical Industries, Lupin, Divi’s Laboratories, Ipca Laboratories and Ajanta Pharma. All five grew revenue in their latest full year, and all five also grew net profit. Lupin has both the lowest P/E at 16.46 and the highest return on equity at 23.76%. Check each valuation against your own risk appetite before acting.
The Nifty Pharma stocks to buy in November 2026 start with five listed names: Sun Pharmaceutical Industries, Lupin, Divi’s Laboratories, Ipca Laboratories and Ajanta Pharma. The Nifty Pharma index tracks India’s listed drug makers, and these five companies are all part of it.
This article ranks none of them as a sure thing. It lays out the numbers each company has reported, how the shares are priced today and what an investor should check before adding any of these Nifty Pharma stocks to buy to a portfolio. All prices are NSE closing prices of 4 November 2026, and financials come from company filings.
Click Here – Get Free Investment Predictions
Which Are the Best Nifty Pharma Stocks to Buy in November 2026?
The best Nifty Pharma stocks to buy in November 2026 for a watchlist are Sun Pharmaceutical Industries, Lupin, Divi’s Laboratories, Ipca Laboratories and Ajanta Pharma. They were picked because each has complete reported financials, profit in the latest quarter and an NSE listing. The table puts their market data side by side.
| Company | CMP (Rs) | Market Cap | P/E | ROE | Dividend Yield |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,773 | Rs 4,22,991 crore | 34.91 | 13.74% | 0.91% |
| Lupin | 2,009 | Rs 91,367 crore | 16.46 | 23.76% | 0.90% |
| Divi’s Laboratories | 10,038 | Rs 2,56,310 crore | 87.63 | 15.32% | 0.31% |
| Ipca Laboratories | 1,972 | Rs 48,860 crore | 35.53 | 14.15% | 0.31% |
| Ajanta Pharma | 3,317 | Rs 43,234 crore | 38.10 | 23.33% | 0.81% |
On valuation, Lupin trades below the industry P/E; Sun Pharmaceutical Industries, Ipca Laboratories and Ajanta Pharma sit close to it; Divi’s Laboratories carries a premium. Valuation is the first filter for any Nifty Pharma stocks to buy list, and it is covered again in the risk section.
Why These Nifty Pharma Stocks to Buy Are in Focus
In this list, FY26 net profit grew for every company and revenue grew by more than 8% for each. The list covers the largest pharma company by market value, a global generics player, an API and custom manufacturing leader, a formulations and ingredients maker and a branded generics specialist. Investors comparing the best Nifty Pharma stocks in India usually check product pipelines, regulatory records and how the shares are valued.
Sun Pharmaceutical Industries: The Pharma Heavyweight Among Nifty Pharma Stocks to Buy
Sun Pharmaceutical Industries is India’s largest pharmaceutical company by market value, with a strong domestic franchise and a growing specialty portfolio in the US. Its market capitalisation is Rs 4,22,991 crore, the share price is Rs 1,773 and the P/E of 34.91 compares with an industry P/E of 37.65.
Over FY26, net profit rose 5.3% to Rs 11,565 crore on revenue of Rs 61,674 crore, which was up 12.7%. The latest quarter, the June 2026 quarter, brought revenue of Rs 16,024 crore, up 11.9% year on year, and net profit of Rs 2,911 crore, up 26.4%.
Return on equity is 13.74%, debt-to-equity is 0.06, and the dividend yield is 0.91%. Promoters hold 52.68%, foreign institutions 14.36% and domestic institutions 22.27% as of September 2026. Domestic institutional holding has risen from 20.23% to 22.27% over the last year.
Lupin: The Global Generics Player Among Nifty Pharma Stocks to Buy
Lupin is a global generics and specialty pharma company with strong respiratory, cardiac and anti-diabetic products. The stock trades at Rs 2,009 with a market capitalisation of Rs 91,367 crore and a P/E of 16.46, against an industry P/E of 37.65.
FY26 revenue rose 26.8% to Rs 29,039 crore and net profit rose 62.0% to Rs 5,355 crore. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit grew 16.0% to Rs 1,417 crore.
Return on equity is 23.76%, debt-to-equity is 0.29, and the dividend yield is 0.90%. Promoters hold 46.84%, foreign institutions 23.28% and domestic institutions 23.78% as of September 2026. Foreign institutional holding has risen from 20.49% to 23.28% over the last year.
Check Nifty Pharma Stocks Live on the Univest Screener
Divi’s Laboratories: The API Specialist Among Nifty Pharma Stocks to Buy
Divi’s Laboratories is a contract manufacturer of active pharmaceutical ingredients and intermediates for global drug makers. At Rs 10,038, the stock has a market capitalisation of Rs 2,56,310 crore and trades at 87.63 times earnings, while the industry P/E is 37.65.
Reported numbers show FY26 revenue of Rs 11,067 crore, up 14.0% year on year, with net profit at Rs 2,568 crore, up 17.2%. The June 2026 quarter added revenue of Rs 3,144 crore (up 24.3%) and net profit of Rs 902 crore (up 65.5%).
Return on equity is 15.32%, debt-to-equity is 0.00, and the dividend yield is 0.31%. Promoters hold 51.88%, foreign institutions 20.38% and domestic institutions 19.17% as of September 2026. A point to keep in view: at a P/E of 87.63, expectations are already high.
Ipca Laboratories: The Formulations and API Name Among Nifty Pharma Stocks to Buy
Ipca Laboratories is a pharma company making formulations and active ingredients, known for anti-malarial and pain-management products. Its market capitalisation is Rs 48,860 crore, the share price is Rs 1,972 and the P/E of 35.53 compares with an industry P/E of 37.65.
Over FY26, net profit rose 51.3% to Rs 1,191 crore on revenue of Rs 9,821 crore, which was up 8.7%. The latest quarter, the June 2026 quarter, brought revenue of Rs 2,813 crore, up 20.2% year on year, and net profit of Rs 423 crore, up 80.4%.
Return on equity is 14.15%, debt-to-equity is 0.10, and the dividend yield is 0.31%. Promoters hold 44.72%, foreign institutions 11.53% and domestic institutions 36.59% as of September 2026. Foreign institutional holding has risen from 10.43% to 11.53% over the last year.
Ajanta Pharma: The Branded Generics Specialist Among Nifty Pharma Stocks to Buy
Ajanta Pharma is a branded generics company with a strong presence in dermatology, ophthalmology and cardiology in India, Africa and Asia. The stock trades at Rs 3,317 with a market capitalisation of Rs 43,234 crore and a P/E of 38.10, against an industry P/E of 37.65.
FY26 revenue rose 18.6% to Rs 5,625 crore and net profit rose 14.7% to Rs 1,056 crore. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit grew 30.9% to Rs 334 crore.
Return on equity is 23.33%, debt-to-equity is 0.06, and the dividend yield is 0.81%. Promoters hold 63.47%, foreign institutions 7.63% and domestic institutions 21.94% as of September 2026. Domestic institutional holding has risen from 17.90% to 21.94% over the last year.
Download the Univest iOS App or Univest Android App to track these Nifty Pharma stocks live and get daily stock recommendations.
Growth Snapshot: Latest Full Year and Latest Quarter
The table compares year-on-year growth in revenue and net profit for all five Nifty Pharma stocks, using filed results.
| Company | Full-Year Revenue Growth | Full-Year Profit Growth | Latest Quarter | Quarter Revenue Growth | Quarter Profit Growth |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 12.7% | 5.3% | Jun 2026 | 11.9% | 26.4% |
| Lupin | 26.8% | 62.0% | Jun 2026 | 32.5% | 16.0% |
| Divi’s Laboratories | 14.0% | 17.2% | Jun 2026 | 24.3% | 65.5% |
| Ipca Laboratories | 8.7% | 51.3% | Jun 2026 | 20.2% | 80.4% |
| Ajanta Pharma | 18.6% | 14.7% | Jun 2026 | 27.7% | 30.9% |
Factors That Move Nifty Pharma Stocks to Buy
Four factors tend to drive Nifty Pharma stocks, and each one is worth checking before a purchase.
- Product mix: Branded and specialty drugs lift margins.
- Export exposure: US sales carry currency effects.
- Regulatory record: Plant inspections matter.
- Valuation: One name trades at a high P/E.
Risks to Keep in Mind Before Buying Nifty Pharma Stocks
The first risk is that pharma earnings depend on regulatory approvals and plant inspections in export markets. The second is valuation, because one of these names trades at a high multiple. Check results every quarter.
On the numbers, Divi’s Laboratories trades at the highest P/E on this list at 87.63, so its earnings need to keep growing to support the price. Nifty Pharma stocks to buy can still fall when markets turn weak, and a staggered entry has historically suited investors better than a lump-sum purchase.
How to Choose Nifty Pharma Stocks to Buy
- Compare growth: Profit growth varies widely here.
- Review P/E: Lupin trades lowest in the group.
- Check ROE: Two earn above 23%.
- Diversify: Mix branded and API businesses.
How to Invest in Nifty Pharma Stocks
- Shortlist two or three companies from this list that match your risk appetite.
- Open the Univest Screener and compare P/E, ROE and debt for each stock.
- Check the latest quarterly results and shareholding pattern on NSE or BSE.
- Decide an amount you can hold for three to five years and split it into two or three purchases.
- Review the holding after every quarterly result instead of reacting to daily price moves.
Conclusion
Lupin offers both the lowest P/E on this list at 16.46 and the highest return on equity at 23.76%, and Lupin posted the fastest net profit growth in its latest full year at 62.0%. Among the best Nifty Pharma stocks in India, these five give investors a spread of size, valuation and growth, so the right pick depends on risk appetite and holding period. Spread the entry, keep position sizes sensible and consult a SEBI-registered advisor before investing in any of these Nifty Pharma stocks to buy.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Nifty Pharma Stocks to Buy
Which are the best Nifty Pharma stocks to buy in November 2026?
Ans. The five Nifty Pharma stocks on the November 2026 watchlist are Sun Pharmaceutical Industries, Lupin, Divi’s Laboratories, Ipca Laboratories and Ajanta Pharma. Lupin has both the lowest P/E at 16.46 and the highest ROE at 23.76%, and Lupin grew net profit 62.0% in its latest full year. This is educational content, not investment advice, so please consult a SEBI-registered advisor.
Is Sun Pharmaceutical Industries a good stock to buy from this Nifty Pharma list?
Ans. Sun Pharmaceutical Industries is the largest company on this list with a market capitalisation of Rs 4,22,991 crore and a P/E of 34.91 against an industry P/E of 37.65. Its FY26 revenue rose 12.7% and net profit rose 5.3%, with return on equity at 13.74%. Whether it suits you depends on your risk appetite and holding period, so please consult a SEBI-registered advisor before investing.
Are these Nifty Pharma stocks expensive right now?
Ans. Valuations vary across the group. Sun Pharmaceutical Industries trades at a P/E of 34.91, Lupin trades at a P/E of 16.46, Divi’s Laboratories trades at a P/E of 87.63, Ipca Laboratories trades at a P/E of 35.53, Ajanta Pharma trades at a P/E of 38.10, against an industry P/E of 37.65. Higher multiples reflect faster growth but also leave less room for earnings misses, so entry price deserves attention.
Which of these Nifty Pharma stocks pay a dividend?
Ans. Dividend yields on this list are Sun Pharmaceutical Industries 0.91%, Lupin 0.90%, Divi’s Laboratories 0.31%, Ipca Laboratories 0.31%, Ajanta Pharma 0.81%. Yields are modest across the group, so most investors look at these stocks for growth in earnings rather than for income, and payouts can change with company profits.
Which stock on this list has the highest return on equity?
Ans. Lupin has the highest ROE on this list at 23.76%, followed by Ajanta Pharma at 23.33% and Divi’s Laboratories at 15.32%. A higher ROE shows a company earns more profit on shareholder capital, but it should be read alongside valuation and debt.
What are the risks of investing in Nifty Pharma stocks?
Ans. The main risks are regulatory approvals and inspections, currency effects on exports and one high valuation. On this list, Divi’s Laboratories trades at the highest P/E of 87.63, which leaves less room for earnings disappointments. Staggered buying and a long holding period can help manage these risks.
How can I invest in Nifty Pharma stocks in India?
Ans. You can buy these stocks directly on NSE or BSE through a demat account, and compare them first on the Univest Screener using P/E, ROE and debt. Many investors split the amount across two or three purchases and review the holding after each quarterly result. Sector-themed mutual funds and ETFs are another route for investors who prefer diversification.
